WHO approves trials for two new Ebola vaccines in DR Congo
WHO approves trials for two new Ebola vaccines in DR Congo
WHO approves trials for two new Ebola vaccines in DR Congo
Key points
اہم نکات
मुख्य बातें
- The World Health Organization has approved clinical trials for two new vaccines designed to fight the Bundibugyo strain of Ebola, which has killed more than 5,300 people in the Democratic Republic of the Congo since May.
- The candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469.
- There is currently no approved vaccine for the Bundibugyo strain; an earlier trial used Ervebo, which targets the Zaire strain.
- The World Health Organization has approved clinical trials for two new vaccines designed to fight the Bundibugyo strain of Ebola, which has killed more than 5,300 people in the Democratic Republic of the Congo since May.
- The candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469.
- There is currently no approved vaccine for the Bundibugyo strain; an earlier trial used Ervebo, which targets the Zaire strain.
- The World Health Organization has approved clinical trials for two new vaccines designed to fight the Bundibugyo strain of Ebola, which has killed more than 5,300 people in the Democratic Republic of the Congo since May.
- The candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469.
- There is currently no approved vaccine for the Bundibugyo strain; an earlier trial used Ervebo, which targets the Zaire strain.
The World Health Organization has approved clinical trials for two new vaccines designed to fight the Bundibugyo strain of Ebola, which has killed more than 5,300 people in the Democratic Republic of the Congo since May. The candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. There is currently no approved vaccine for the Bundibugyo strain; an earlier trial used Ervebo, which targets the Zaire strain. The trial is led by the DRC's National Institute for Biomedical Research, with results expected in early 2027.
The World Health Organization has approved clinical trials for two new vaccines designed to fight the Bundibugyo strain of Ebola, which has killed more than 5,300 people in the Democratic Republic of the Congo since May. The candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. There is currently no approved vaccine for the Bundibugyo strain; an earlier trial used Ervebo, which targets the Zaire strain. The trial is led by the DRC's National Institute for Biomedical Research, with results expected in early 2027.
The World Health Organization has approved clinical trials for two new vaccines designed to fight the Bundibugyo strain of Ebola, which has killed more than 5,300 people in the Democratic Republic of the Congo since May. The candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. There is currently no approved vaccine for the Bundibugyo strain; an earlier trial used Ervebo, which targets the Zaire strain. The trial is led by the DRC's National Institute for Biomedical Research, with results expected in early 2027.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।